Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. - Université de Lille Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2019

Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.

Catherine J Lee
  • Fonction : Auteur
Dietrich Beelen
  • Fonction : Auteur
Jurgen Finke
  • Fonction : Auteur
Didier Blaise
Arnold Ganser
  • Fonction : Auteur
Maija Itala-Remes
  • Fonction : Auteur
Patrice Chevallier
  • Fonction : Auteur
Helene Labussiere-Wallet
  • Fonction : Auteur
Johan Maertens
  • Fonction : Auteur
Jean-Henri Bourhis
  • Fonction : Auteur
Audrey Mailhol
  • Fonction : Auteur
Bipin N Savani
  • Fonction : Auteur
Arnon Nagler
  • Fonction : Auteur

Résumé

Therapy-related acute myeloid leukemia (t-AML) arises as a late complication following antecedent solid tumors or hematologic diseases and their associated treatments. There are limited data regarding risk factors and outcomes following allogeneic hematopoietic cell transplantation (HCT) for t-AML following a prior solid tumor, and furthermore, the impact of myeloablative (MAC) vs reduced-intensity conditioning (RIC) on survival is unknown. The acute leukemia working party (ALWP) of the European society for blood and bone marrow transplantation (EBMT) performed a large registry study that included 535 patients with t-AML and prior solid tumor who underwent first MAC or RIC allogeneic HCT from 2000-2016. The primary endpoints of the study were OS and LFS. Patients receiving RIC regimens had an increase in relapse incidence (hazard ratio [HR], 1.52; 95% confidence interval [CI] 1.02-2.26; P = 0.04), lower LFS (HR, 1.52; 95% CI 1.12-2.05, P = 0.007), and OS (HR, 1.51; CI 1.09-2.09; P = 0.012). There were no differences in NRM and GRFS. Importantly, LFS and OS were superior in patients receiving ablative regimens due to a decrease in relapse. As NRM continues to decline in the current era, it is conceivable that outcomes of HCT for t-AML with prior solid tumor may be improved by careful patient selection for myeloablative regimens.

Dates et versions

hal-04412197 , version 1 (23-01-2024)

Identifiants

Citer

Catherine J Lee, Myriam Labopin, Dietrich Beelen, Jurgen Finke, Didier Blaise, et al.. Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.. American Journal of Hematology, 2019, American Journal of Hematology, 94, pp.431-438. ⟨10.1002/ajh.25395⟩. ⟨hal-04412197⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More